Tryp Therapeutics has completed psychotherapy training for its upcoming Phase 2a psilocybin clinical trial.
Tryp Therapeutics has completed the training of psychotherapists for its clinical trial at the University of Florida using synthetic psilocybin in combination with psychotherapy for overeating disorders.
Conducted by Fluence, which is led by researchers and psychotherapists with direct experience in psychedelic clinical trials, Tryp says the training represents a best-in-class approach for psychotherapy that will accompany the administration of psilocybin.
Overeating disorders
The company says that both pharmaceutical and psychological processes will play a synergistic role to determine outcomes for TRP-8802, an oral formulation of synthetic psilocybin, and that psychotherapy is an integral part of its novel treatment methods to create the proper mindset for the neuroplasticity benefits of psilocybin to take full effect.
For the trial, which will be conducted with the University’s Jennifer Miller, M.D., participants will undergo preparatory psychotherapy sessions leading to two dosing sessions, which will be followed up with multiple integration sessions with the therapists.
Director of the Behavioral Health and Technology Research Clinic and professor in the Department of Psychology at the University of Florida, Jesse Dallery, Ph.D., said: “Establishing definitive guidelines and training for the psychotherapy portion of psychedelic therapies is essential to minimizing variability and optimizing the patient experience. I was thoroughly impressed with the rigor and scientific basis of the training provided by Fluence for our upcoming study with Tryp Therapeutics and look forward to initiating our work with patients later this year.”
President and CSO of Tryp, Jim Gilligan, Ph.D., added: “We continue to be amazed by the complexity of neural networks and the array of biological and behavioural factors that influence the healthy functioning of the brain and body.
“Our partners at the University of Florida have shown tremendous commitment to the effective administration of psychotherapy for our upcoming Phase 2a clinical trial, and Fluence continues to be an exceptional partner for the design and implementation of this important component of our therapies. The completion of this psychotherapy training marks a significant milestone for Tryp, as it remains an integral part of our novel treatment.”
Tryp Therapeutics, Fluence and the University of Florida have collaborated to create a comprehensive training manual for the psychotherapy portion of Tryp’s psychedelic treatment regimen that will be adapted for subsequent clinical trials in fibromyalgia and other chronic pain indications.
